Drug intelligence / Profile preview

Lp2-CAR-T

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Lp2-CAR-T is a third-generation chimeric antigen receptor T cell (CAR-T) therapy engineered to target **podoplanin (PDPN)**, a glycoprotein overexpressed in various cancers, notably glioblastoma. This CAR utilizes a cancer-specific monoclonal antibody (CasMab, LpMab-2) for antigen recognition, allowing selective targeting of **PDPN-positive cancer cells** while sparing normal cells expressing PDPN. Lp2-CAR-T cells have demonstrated preclinical efficacy against glioma and glioma stem cells and can be used in combination with the oncolytic virus G47Δ to enhance anti-tumor response. Primary development emphasizes treatment of **glioblastoma**[1].

Other names: LpMab-2 CAR-TLpMab2 CAR-TLpMab 2 CAR-TCasMab Lp2 CAR-T

Targets

PDPN (Podoplanin)

Beyond the preview

Go deeper on Lp2-CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lp2-CAR-T.

Explore the full profile